HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family. It is localized within the cytoplasm and has unique substrate specificities for nonhistone proteins, such as α‐tubulin. Furthermore, it plays a major role in protein aggregate formation and recently was demonstrated to interact with the microtubule associated protein tau and tau was identified as a possible substrate for HDAC6 in neurons. This study was undertaken to investigate whether HDAC6 is present in oligodendrocytes and whether it is involved in tubulin and tau acetylation in these cells. We show for the first time that HDAC6 is expressed in cultured rat brain oligodendrocytes. Its inhibition by the specific HDAC6 inhibitor tubastatin A (TST) leads to morphological alterations, microtubule bundling, and tubulin acetylation, and changes in tau‐isoform expression and phosphorylation. Furthermore, the microtubule binding activity of tau was reduced. Using the oligodendroglial cell lines OLN‐t40 and OLN‐t44, which were genetically engineered to express either the longest human tau isoform with four microtubule binding repeats (4R‐tau), or the shortest tau isoform with three repeats (3R‐tau), respectively, we demonstrate that tau is acetylated by HDAC6 within the 4R‐binding domain. Tau acetylation reduced its turnover rate and acetylated tau was degraded slower in these cells. TST and shRNA‐mediated knockdown of HDAC6 in oligodendroglia cells caused an increase in pathological hyperphosphorylated tau detectable with the 12E8 antibody. Hence HDAC6 and dysregulation of the deacetylation and acetylation process in oligodendrocytes may contribute to diseases with oligodendroglial pathology. GLIA 2014;62:535–547
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Tau is a major constituent of proteinaceous cell inclusions in nerve cells and glia in a variety of neurodegenerative diseases termed tauopathies (Ballatore et al., 2007; Himmelstein et al., 2012).”
BackgroundSirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008 · cited 1×
“…been correlated with higher levels of stability in mature cells (Song et al., 2001) and deacetylation was connected with the deacetylase SIRT2 (silent information regulator type 2), a member of the separate class III NAD1 dependent HDACs (for review see Houtkooper et al., 2012; Li et al., 2007).”
BackgroundHDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS.
Pandey, U. B., Nie, Z., Batlevi, Y., McCray, B. A., Ritson, G. P., Nedelsky, N. B., Schwartz, S. L., DiProspero, N. A., Knight, M. A., Schuldiner, O., et al. (2007) · Nature · doi:10.1038/nature05853 · Cited by 1,234 · cited 1×
“It is a key element in protein aggregate formation and in the clearing process of protein aggregates (Boyault et al., 2006; Kawaguchi et al., 2003; Pandey et al., 2007).”
BackgroundAcetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy
Min, S.-W., Cho, S.-H., Zhou, Y., Schroeder, S., Haroutunian, V., Seeley, W. W., Huang, E. J., Shen, Y., Masliah, E., Mukherjee, C., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.08.044 · Cited by 949
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801 · cited 2×
“Recently, the derivative tubastatin A was developed with a much higher selectivity for the catalytic domain of HDAC6 and a higher lipophilicity than tubacin (Butler et al., 2010; Simoes-Pires et al., 2013).”
BackgroundBiernat, J., Gustke, N., Drewes, G., Mandelkow, E., & Mandelkow, E. (1993) · Neuron · doi:10.1016/0896-6273(93)90279-z · Cited by 796
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg115 · Cited by 740 · cited 1×
“…dependent on the second catalytic domain of HDAC6 which is affected by specific inhibitors such as tubacin and tubastatin A (Haggarty et al., 2003; Zhang et al., 2003; Zilberman et al., 2009). a2Tubulin acetylation, occurring on polymerized MTs, has been connected to an increase in stability, but…”
BackgroundThe acetylation of tau inhibits its function and promotes pathological tau aggregation
Cohen, T. J., Guo, J. L., Hurtado, D. E., Kwong, L. K., Mills, I. P., Trojanowski, J. Q., & Lee, V. M. Y. (2011) · Nature Communications · doi:10.1038/ncomms1255 · Cited by 724 · cited 8×
“Using polyclonal antibodies specifically directed against acetylated K280 tau (Cohen et al., 2011), acetylated tau (actau) was detectable in low amounts in OLN-t40 cells and increased after the treatment with TST (Fig.”
BackgroundInfluentialIn vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation
Matsuyama, A., Shimazu, T., Sumida, Y., Saito, A., Yoshimatsu, Y., Seigneurin‐Berny, D., Osada, H., Komatsu, Y., Nishino, N., Khochbin, S., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf682 · Cited by 720 · cited 1×
“It is acetylated at lysine 40 and acetylation occurs mainly on polymerized MTs, while deacetylation has been observed preferentially on depolymerized tubulin (Matsuyama et al., 2002).”
BackgroundMultiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676 · cited 2×
“…nuclear enzymes catalyzing the deacetylation of histone proteins thereby influencing many cellular processes, including gene expression, remodelling chromatin structure, cell cycle regulation, and developmental events (Chuang et al., 2009; Liu and Casaccia, 2010; True and Matthias, 2012).”
Background
Cited by
The complexity of tau in Alzheimer’s disease
Naseri, N. N., Wang, H., Guo, J., Sharma, M., & Luo, W. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.022 · Cited by 373
Lysine Acetylation Goes Global: From Epigenetics to Metabolism and Therapeutics
Ali, I., Conrad, R. J., Verdin, E., & Ott, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00181 · Cited by 366
Trzeciakiewicz, H., Ajit, D., Tseng, J.-H., Chen, Y., Ajit, A., Tabassum, Z., Lobrovich, R., Peterson, C., Riddick, N. V., Itano, M. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19317-4 · Cited by 102
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Seiberlich, V., Bauer, N. G., Schwarz, L., Ffrench‐Constant, C., Goldbaum, O., & Richter‐Landsberg, C. (2015) · Glia · doi:10.1002/glia.22832 · Cited by 84
“OLN-93 cells (Richter-Landsberg and Heinrich, 1996) stably transfected with the longest human tau isoform (OLN-t40) 1622 Volume 63, No. 9 and the shortest human tau isoform (OLN-t44) were used (Bauer and Richter-Landsberg, 2006; Noack et al., 2014).”
MethodSelf-citation
Metadata
- Authors
- Noack, M., Leyk, J., & Richter‐Landsberg, C.
- Venue
- Glia
- Publisher
- Wiley
- Published
- 2014-01-24
- Volume
- 62
- Issue
- 4
- Pages
- 535-547
- ISSN
- 0894-1491 (ISSN-L)
- 1098-1136
- OpenAlex
- W1646733602
- Cited by
- 77
- References
- 19
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes. https://app.cochat.ai/papers/10.1002/glia.22624
- The paper
- Noack, M., Leyk, J., & Richter‐Landsberg, C. (2014). HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes. Glia. https://doi.org/10.1002/glia.22624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.